Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 14/20 | 0.57 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | TYK2 | P29597 | 3/20 | 0.56 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26279281 | 0.92 | ABL1 (0.55) | MAP4K1ABL1JAK2TYK2JAK1 | |
| SCHEMBL26279287 | 0.89 | ABL1 (0.55) | MAP4K1ABL1JAK2TYK2CDK9 | |
| SCHEMBL20073388 | 0.85 | MEN1 (0.57) | MAP4K1ABL1JAK2TYK2ACVRL1 | |
| SCHEMBL22647518 | 0.84 | MAP4K1 (0.53) | MAP4K1ABL1JAK2TYK2ACVRL1 | |
| SCHEMBL26677550 | 0.83 | TYK2 (0.53) | MAP4K1ABL1JAK2TYK2JAK1 | |
| SCHEMBL20073384 | 0.83 | MAP4K1 (0.52) | MAP4K1ABL1JAK2TYK2ACVRL1 | |
| SCHEMBL27124011 | 0.82 | MAP4K1 (0.57) | MAP4K1ABL1JAK2TYK2 | |
| Lithium Ion SCHEMBL27199584 | 0.82 | MAP4K1 (0.51) | MAP4K1ABL1JAK2TYK2ACVRL1 | |
| SCHEMBL30050794 | 0.81 | ABL1 (0.50) | MAP4K1ABL1JAK2TYK2 | |
| SCHEMBL22647309 | 0.81 | ABL1 (0.50) | MAP4K1ABL1JAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109954-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124448-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | MAP4K1 160/4885ABL1 6/4885JAK2 2/4885 |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | TYK2, JAK2, JAK1 | MAP4K1 160/4885ABL1 6/4885JAK2 2/4885 |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | TYK2, JAK2, JAK1 | MAP4K1 160/4885ABL1 6/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.